Dorsey & Whitney Trust CO LLC Acquires 145 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Dorsey & Whitney Trust CO LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 40.2% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 506 shares of the biopharmaceutical company’s stock after purchasing an additional 145 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in Regeneron Pharmaceuticals were worth $266,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of REGN. PGGM Investments boosted its holdings in Regeneron Pharmaceuticals by 159.7% in the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock valued at $44,308,000 after purchasing an additional 51,900 shares during the period. Founders Capital Management LLC boosted its stake in Regeneron Pharmaceuticals by 7.0% during the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock valued at $4,344,000 after buying an additional 538 shares during the period. Sepio Capital LP grew its position in Regeneron Pharmaceuticals by 33.1% during the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock worth $2,150,000 after buying an additional 842 shares in the last quarter. Generate Investment Management Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $6,300,000. Finally, Bellecapital International Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 32.7% during the 2nd quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock valued at $13,389,000 after acquiring an additional 6,283 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 3.1%

NASDAQ REGN opened at $702.75 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $800.99. The stock has a market capitalization of $73.86 billion, a PE ratio of 16.83, a PEG ratio of 2.03 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72. The business’s 50-day moving average is $608.00 and its 200 day moving average is $573.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter last year, the business posted $12.46 EPS. The business’s revenue was up .9% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 8.43%.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of research reports. Morgan Stanley decreased their price objective on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday. Rothschild & Co Redburn assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They issued a “buy” rating and a $890.00 target price on the stock. Sanford C. Bernstein boosted their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 27th. Finally, Jefferies Financial Group upped their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research report on Wednesday, August 27th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $772.76.

Insider Activity

In related news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.